NCT06673693

Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma

Neoadjuvant SBRT Sequential Tislelizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase II Clinical Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Exploring the efficacy and safety of Tislelizumab combined with stereotactic body radiation therapy (SBRT) as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (HNSCC).

Conditions

• Head and Neck Squamous Cell Carcinoma (HNSCC)
• HNSCC

Interventions

Type	Name	Description
DRUG	Tislelizumab	SBRT

Timeline

• Start date: 2025-04-15
• Primary completion: 2027-12-31
• Completion: 2029-12-31
• First posted: 2024-11-05
• Last updated: 2025-04-16

Locations

2 sites across 1 country: China